Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.04 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | hard to drug | 0.27 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 4 Parkinson's papers of 345 | 0.79 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 6078
Sealed predictions
- S100A2 in dopamine neurons, braak-0.46 (p 0.216) → -0.37 (p 0.329)receipt 6085
Swarm cases
receipt 6085: S100A2 in dopamine neurons, braak
- power
- full sample -0.45 (p 0.063, n 18), 95% CI -0.76 to +0.03. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.58 (p 0.013, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.54 (p 0.020, n 18). not the mix.
- skeptic
- leave-one-out range -0.62 to -0.38, sign flips 0; without severely affected donors -0.45 (p 0.063, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for S100A2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts